Therefore, inhibition of STAT1/HMGB1 may enhance cisplatin chemotherapy in tumors and protect kidneys from chronic nephrotoxicity, an intriguing possibility that requires further tests in tumor-bearing animal models. Here, STAT1 is linked to neoplasm.